Fletcher Biosciences

Fletcher Biosciences is a private, pre-clinical stage biotech leveraging a novel protein engineering platform to develop next-generation immunotherapies. The company's approach involves redesigning natural antigen scaffolds to create biologics capable of precisely targeting and eliminating pathogenic T cells driving autoimmune disorders. While still early-stage, its technology holds promise for addressing complex immune-mediated diseases, though it faces significant scientific and competitive risks inherent to the field. The company appears to be in a venture-backed R&D phase, building its platform and pipeline.

Proprietary protein engineering platform that redesigns natural antigen scaffolds to create biologics capable of programmatically eliminating autoreactive T cells and restoring immune balance.

Fletcher operates in the competitive field of antigen-specific immunotherapies for autoimmunity, competing with companies like Anokion, Apellis (via its Cabaletta Bio partnership), and Immunovant, as well as internal programs at large pharmaceutical companies. Its differentiation hinges on the specifics of its proprietary protein design platform, which remains undisclosed.